These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21364589)

  • 21. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model.
    Ray KC; Bell KM; Yan J; Gu G; Chung CH; Washington MK; Means AL
    PLoS One; 2011 Feb; 6(2):e16786. PubMed ID: 21311774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status.
    Metildi CA; Kaushal S; Hoffman RM; Bouvet M
    J Surg Res; 2013 Sep; 184(1):290-8. PubMed ID: 23590868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer.
    Huang W; Hua H; Xiao G; Yang X; Yang Q; Jin L
    Aging (Albany NY); 2021 Jul; 13(14):18482-18497. PubMed ID: 34319912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival in ampullary cancer: potential role of different KRAS mutations.
    Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
    Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
    Ray KC; Moss ME; Franklin JL; Weaver CJ; Higginbotham J; Song Y; Revetta FL; Blaine SA; Bridges LR; Guess KE; Coffey RJ; Crawford HC; Washington MK; Means AL
    Oncogene; 2014 Feb; 33(7):823-31. PubMed ID: 23376846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer.
    Jorgenson TC; Williams BR; Wendland A; Bilger A; Sandgren EP; Drinkwater NR
    Cancer Res; 2010 Nov; 70(21):8398-406. PubMed ID: 20959479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
    Huang M; Tang SN; Upadhyay G; Marsh JL; Jackman CP; Srivastava RK; Shankar S
    Cancer Lett; 2014 Oct; 353(1):32-40. PubMed ID: 25050737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of Heterozygosity for
    Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.
    Sudhir PR; Chen CH; Pavana Kumari M; Wang MJ; Tsou CC; Sung TY; Chen JY; Chen CH
    Mol Cell Proteomics; 2012 Oct; 11(10):901-15. PubMed ID: 22761399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
    Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
    Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
    Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
    Hu X; Zhang R; Yao J; Mu B; Zhao C
    Mol Med Rep; 2023 Jan; 27(1):. PubMed ID: 36367161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
    Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
    von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
    Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.
    Hindul NL; Abbott LR; Adan SMD; Straatman KR; Fry AM; Hirota K; Tanaka K
    J Biol Chem; 2024 Jun; 300(6):107409. PubMed ID: 38796063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.